Carvedilol

DRUG INFORMATION

  ADULT
    - ( 2 ) Heart failure: Start at 10 mg once daily and increase to 20 mg, 40 mg, and
      then 80 mg once daily over intervals of at least 2 weeks.
      Source: US FDA label for carvedilol (Carvedilol Phosphate), section 'dosage and
      administration', retrieved 2026-08-29
    - ( 2.1 ) Left ventricular dysfunction following myocardial infarction: Start at 20
      mg once daily and increase to 40 mg then 80 mg once daily after intervals of 3 to
      10 days.
      Source: US FDA label for carvedilol (Carvedilol Phosphate), section 'dosage and
      administration', retrieved 2026-08-29
    - ( 2.2 ) Hypertension: Start at 20 mg once daily and increase if needed for blood
      pressure control to 40 mg then 80 mg once daily over intervals of 1 to 2 weeks.
      Source: US FDA label for carvedilol (Carvedilol Phosphate), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - Carvedilol phosphate extended-release capsules are intended for once-daily
      administration. Patients controlled with immediate-release carvedilol tablets
      alone or in combination with other medications may be switched to carvedilol
      phosphate extended-release capsules based on the total daily doses shown in Table
      1. Table 1.
      Source: This line points to a numbered table that this card does not show - read
      that table in the label before you dose. US FDA label for carvedilol (Carvedilol
      Phosphate), section 'dosage and administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - Patients at risk appear to be those with low blood pressure (systolic blood
      pressure less than 100 mm Hg), ischemic heart disease and diffuse vascular
      disease, and/or underlying renal insufficiency.
      Source: US FDA label for carvedilol (Carvedilol Phosphate), section 'warnings and
      cautions', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - Concomitant administration with a diuretic can be expected to produce additive
      effects and exaggerate the orthostatic component of carvedilol action. 2.4 Hepatic
      Impairment Carvedilol phosphate extended-release capsules should not be given to
      patients with severe hepatic impairment [see Contraindications (4) ] .
      Source: US FDA label for carvedilol (Carvedilol Phosphate), section 'dosage and
      administration', retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Available data regarding use of carvedilol phosphate extended-release
      capsules in pregnant women are insufficient to determine whether there are drug-
      associated risks of adverse developmental outcomes.
      Source: US FDA label for carvedilol (Carvedilol Phosphate), section 'pregnancy',
      retrieved 2026-08-29
    - There are risks to the mother and fetus associated with poorly controlled
      hypertension in pregnancy.
      Source: US FDA label for carvedilol (Carvedilol Phosphate), section 'pregnancy',
      retrieved 2026-08-29
    - The use of beta blockers during the third trimester of pregnancy may increase the
      risk of hypotension, bradycardia, hypoglycemia, and respiratory depression in the
      neonate [see Clinical Considerations ] .
      Source: US FDA label for carvedilol (Carvedilol Phosphate), section 'pregnancy',
      retrieved 2026-08-29

  BREASTFEEDING
    - Risk Summary There are no data on the presence of carvedilol in human milk, the
      effects on the breastfed infant, or the effects on milk production.
      Source: US FDA label for carvedilol (Carvedilol Phosphate), section 'nursing
      mothers', retrieved 2026-08-29
    - Carvedilol is present in the milk of lactating rats.
      Source: US FDA label for carvedilol (Carvedilol Phosphate), section 'nursing
      mothers', retrieved 2026-08-29
    - The developmental and health benefits of breastfeeding should be considered along
      with the mother’s clinical need for carvedilol phosphate extended-release capsules
      and any potential adverse effects on the breastfed infant from carvedilol
      phosphate extended-release capsules or from the underlying maternal condition.
      Source: US FDA label for carvedilol (Carvedilol Phosphate), section 'nursing
      mothers', retrieved 2026-08-29